Abstract:Purpose To synthesize the dimer of GX1 and identify whether its affinity and targeting are better than those of GX1. To prepare Ga-68-DOTA-KEK-(GX1)(2) and to apply it to PET and Cerenkov imaging of gastric cancer.</p> Methods Ga-68-DOTA-KEK-(GX1)(2) was prepared, and the labeling yield and stability were determined. Its specificity and affinity were verified using an in vitro cell binding assay and competitive inhibition test, cell immunofluorescence, and cell uptake and efflux study. Its tumor-targeting ability was determined by nano PET/CT and Cerenkov imaging, standardized uptake value (SUV), signal-to-background ratio (SBR) quantification, and a biodistribution study in tumor-bearing nude mice.</p> Results Ga-68-DOTA-KEK-(GX1)(2) was successfully prepared, and the labeling yield was more than 97%. It existed stably for 90 min in serum. The binding of Ga-68-DOTA-KEK-(GX1)(2) to cocultured HUVECs (Co-HUVECs) was higher than that to human umbilical vein endothelial cells (HUVECs), BGC823 cells, and GES cells. It was also higher than that of Ga-68-DOTA-GX1, indicating that the dimer did improve the specificity and affinity of GX1. The binding of KEK-(GX1)(2) to Co-HUVECs was significantly higher than that of GX1. Additionally, the uptake of Ga-68-DOTA-KEK-(GX1)(2) by Co-HUVECs was higher than that of Ga-68-DOTA-GX1 and reached a maximum at 60 min. Nano PET/CT and Cerenkov imaging showed that the tumor imaging of the nude mice injected with Ga-68-DOTA-KEK-(GX1)(2) was clear, and the SUV and SBR value of the tumor sites were significantly higher than those of the nude mice injected with Ga-68-DOTA-GX1, indicating that the probe had better targeting in vivo. Finally, the biodistribution showed quantitatively that when organs such as the kidney and liver metabolized rapidly, the radioactivity of the tumor site of the nude mice injected with Ga-68-DOTA-KEK-(GX1)(2) decreased relatively slowly. At the same time, the percentage of injected dose per gram (%ID/g) of the tumor site was higher than that of other normal organs except the liver and kidney at 60 min, which indicated that the tumor had good absorption of the probe.</p> Conclusion GX1 was modified successfully, and the in vivo and in vitro properties of the GX1 dimer were significantly better than those of GX1. The imaging probe, Ga-68-DOTA-KEK-(GX1)(2), was successfully prepared, which provides a candidate probe for PET and Cerenkov diagnosis of gastric cancer.</p>

Preparation of 90Y-Labeled Different Cyclic RGD Peptides and Evaluation in Nude Mice Bearing Human Glioma Xenografts

<SUP>68</SUP>Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

Imaging of 99Tcm-Cycllc RGD Tetramer in Nude Mice Bearing U87MG Human Glioma Xenografts

Potential Therapeutic Radiotracers: Preparation, Biodistribution and Metabolic Characteristics of 177 Lu-labeled Cyclic RGDfK Dimer

Imaging of 99Tcm-Labeled New Cyclic RGDfK Dimer in Nude Mice Bearing U87MG Human Glioma Xenografts

Improving Tumor Uptake and Excretion Kinetics of 99Mtc-Labeled Cyclic Arginine-Glycine-aspartic (RGD) Dimers with Triglycine Linkers.

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Two ⁹⁰Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy.

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

Preparation of ~(177)Lu-DOTA/DTPA-Bz-Cys-RGD Dimer and Biodistribution Evaluation in Normal Mice

Evaluation of<sup>111</sup>In-Labeled Cyclic RGD Peptides: Tetrameric not Tetravalent

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Evaluation Of In-111-Labeled Cyclic Rgd Peptides: Tetrameric Not Tetravalent

Construction of 131I-RGDyC-PEG-PAMAM-DTX targeted drug delivery system and study of its physicochemical properties and biological activity

Improving Tumor Uptake and Pharmacokinetics of (64)Cu-Labeled Cyclic RGD Peptide Dimers with Gly(3) and PEG(4) Linkers.

Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

68 Ga-labeled Cyclic RGD Dimers with Gly 3 and PEG 4 Linkers: Promising Agents for Tumor Integrin Α V Β 3 PET Imaging

Design, Activity Determination and 99mtc Labeling of Cyclic RGD Dimer for Targeting Integrin Αvβ3

Preparation of 99Tcm labeled cyclic RGDfK dimer and its in vitro and in vivo evaluation